PTCT PTC Therapeutics, Inc. - Common Stock
$73,37
Cena · Sie 18, 2026
Dane fundamentalne na dzień Lip 30, 2026
Zakres 52 tyg.
$48–$91
59% of range
Ocena Analityków
BUY
21 analysts
Cena Docelowa
$98
+33% upside
P/E (TTM)
9.4
ROE
-331.5%
Marża Zysku Netto
39.4%
O PTC Therapeutics, Inc. - Common Stock Przegląd firmy z Wikipedii
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Czytaj więcej
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
PTCT Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$73.36
Kapitalizacja Rynkowa
$5.98B
P/E (TTM)
9.4
EPS (TTM)
$7.78
Przychody (TTM)
$1.73B
Stopa dywidendy
—
ROE
-331.5%
D/E Dług/Kapitał
-1.4
Zakres 52 tyg.
$48 – $91
PTCT Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$1.73B
2016-12-31
→
2025-12-31
EPS
$7.78
2019-12-31
→
2025-12-31
Wolny przepływ pieniężny
$702M
2016-12-31
→
2025-12-31
Marże
39.4%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
PTCT
Mediana porównawcza
P/E (TTM)
9.4
37.2
P/S (TTM)
3.5
9.9
P/B
-29.1
8.3
EV / EBITDA
4.8
—
Price / FCF (Cena / FCF)
8.5
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
PTCT
Mediana porównawcza
Operating Margin (Marża Operacyjna)
50.1%
—
Net Profit Margin (Marża Zysku Netto)
39.4%
-15.1%
ROA
29.7%
-23.3%
ROE
-331.5%
-30.6%
ROIC
1044.7%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
PTCT
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
-1.4
—
Current Ratio (Wskaźnik bieżący)
2.3
6.3
Quick Ratio (Wskaźnik Szybkości)
2.2
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
PTCT
Mediana porównawcza
Revenue YoY (Przychody R/R)
114.5%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
35.3%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
35.4%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
PTCT
Mediana porównawcza
PTCT Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
21 analityków
- Mocne kupno 6 28,6%
- Kup 11 52,4%
- Trzymaj 3 14,3%
- Sprzedaj 1 4,8%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
14 analityków · 2026-08-13
Mediana
$98.00
Teraz
$73.36
Niski
$70.00
Wysoki
$130.00
Średni cel
$98.00
+33,6%
Średnia cel
$97.86
+33,4%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
1.9%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $0.92 | $0.43 | 0.49% |
| 31 marca 2026 | $-0.03 | $-0.48 | 0.45% |
| 31 grudnia 2025 | $-1.67 | $0.04 | -1.7% |
| 30 września 2025 | $0.20 | $-1.40 | 1.6% |
| 30 czerwca 2025 | $-0.83 | $-1.08 | 0.25% |
| 31 marca 2025 | $10.04 | $-0.22 | 10.3% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | — |
| ERAS | $1.06B | -8.5 | — | — | -35.7% | — |
| SRRK | $4.78B | -13.4 | — | — | -157.9% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 15
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Bilans 27
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Przepływy pieniężne 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 13
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | -155,203,905 | 78,471,119 | 78,151,240 | 78,115,836 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | -163,341,037 | 87,115,369 | 78,151,240 | 86,385,922 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Bilans 27
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Przepływy pieniężne 13
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Wycena (TTM) 13
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.02B | $1.84B | · | $1.76B | $1.74B | $1.77B | · | $790M | $807M | $841M | · | $848M | $817M | $752M | · | $670M | |
| Net Income TTM | $32M | $815M | · | $711M | $596M | $569M | · | $-430M | $-523M | $-562M | · | $-580M | $-599M | $-527M | · | $-522M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | 313.7 | 7.3 | · | 7.7 | 7.5 | 8.3 | · | -6.6 | -4.4 | -3.9 | · | -2.9 | -5.0 | -6.6 | · | -6.8 | |
| P/S | 6.6 | 3.1 | · | 2.8 | 2.2 | 2.3 | · | 3.6 | 2.9 | 2.7 | · | 2.0 | 3.8 | 4.8 | · | 5.4 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| P / FCF | · | -93.7 | · | · | · | 4.6 | · | · | · | 36.5 | · | · | · | -90.2 | · | · | |
| EV / EBITDA | 34.6 | 66.9 | · | 1161.8 | -62.2 | 2.3 | · | -39.0 | -38.4 | 163.9 | · | -16.7 | -15.7 | -51.8 | · | -52.8 | |
| EV / FCF | · | -67.1 | · | · | · | 2.6 | · | · | · | 26.6 | · | · | · | -97.4 | · | · | |
| EV / Revenue | 5.0 | 2.2 | · | 2.0 | 1.3 | 1.3 | · | 2.7 | 1.9 | 1.9 | · | 2.3 | 4.0 | 5.1 | · | 5.4 | |
| Earnings Yield | 0.32% | 13.8% | · | 13.1% | 13.4% | 12.1% | · | -15.2% | -22.6% | -25.8% | · | -34.9% | -20.2% | -15.1% | · | -14.6% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $1.73B | $807M | $938M | $699M | $539M |
| Marża Operacyjna % | 50.1% | -37.5% | -46.9% | — | -69.5% |
| Zysk netto | $683M | $-363M | $-627M | $-559M | $-524M |
| Rozwodniony EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -1.4 | -0.3 | -0.3 | — | 300.0 |
| Wskaźnik bieżący | 2.3 | 2.4 | 2.0 | — | 1.9 |
| Wskaźnik Szybkości | 2.2 | 2.2 | 1.7 | — | 1.7 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $702M | $-114M | $-187M | — | $-280M |
Sygnały transakcyjne Ostatnie sygnały kupna/sprzedaży z ceną wejścia i wskaźnikiem ryzyka/zysku
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 403 emitenci · $5.4B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 83 (+22 vs poprzedni kw.) | 43 (-9 vs poprzedni kw.) | 133 (-4 vs poprzedni kw.) | 109 (+6 vs poprzedni kw.) | +2.1M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | $631 875 072 | 7 746 415 | 11,70% | Akcje |
| JANUS HENDERSON GROUP PLC | $479 178 655 | 7 034 622 | 8,87% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401 986 014 | 4 928 111 | 7,45% | Akcje |
| STATE STREET CORP | $375 136 515 | 4 598 952 | 6,95% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $305 000 589 | 3 739 127 | 5,65% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $292 435 873 | 3 585 091 | 5,42% | Akcje |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159 563 645 | 1 956 156 | 2,96% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $155 132 041 | 1 901 417 | 2,87% | Akcje |
| Hood River Capital Management LLC | $141 818 662 | 1 738 613 | 2,63% | Akcje |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140 519 660 | 1 722 688 | 2,60% | Akcje |
| TANG CAPITAL MANAGEMENT LLC | $122 355 000 | 1 500 000 | 2,27% | Akcje |
| Driehaus Capital Management LLC | $117 469 528 | 1 440 107 | 2,18% | Akcje |
| Jefferies Financial Group Inc. | $110 693 916 | 1 357 042 | 2,05% | Akcje |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94 361 749 | 1 156 819 | 1,75% | Akcje |
| Pictet Asset Management Holding SA | $93 629 635 | 1 147 844 | 1,73% | Akcje |
| ARMISTICE CAPITAL, LLC | $87 393 690 | 1 071 395 | 1,62% | Akcje |
| Blue Sparrow, LLC /DE | $85 705 599 | 1 050 700 | 1,59% | Akcje |
| D. E. Shaw & Co., Inc. | $77 478 857 | 949 845 | 1,44% | Akcje |
| Palo Alto Investors LP | $74 950 268 | 918 846 | 1,39% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64 449 436 | 790 112 | 1,19% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $59 015 895 | 723 500 | 1,09% | Akcje |
| Boston Partners | $57 080 953 | 699 871 | 1,06% | Akcje |
| FMR LLC | $56 956 987 | 698 259 | 1,05% | Akcje |
| BANK OF AMERICA CORP /DE/ | $56 350 840 | 690 828 | 1,04% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53 377 940 | 654 382 | 0,99% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $51 486 821 | 631 199 | 0,95% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $47 953 943 | 587 887 | 0,89% | Akcje |
| Ensign Peak Advisors, Inc | $41 442 128 | 508 056 | 0,77% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $40 866 277 | 500 995 | 0,76% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36 050 432 | 441 957 | 0,67% | Akcje |
| Parkman Healthcare Partners LLC | $35 539 315 | 435 691 | 0,66% | Akcje |
| LOOMIS SAYLES & CO L P | $35 387 921 | 433 835 | 0,66% | Akcje |
| Defilade Capital Management, L.P. | $35 376 827 | 433 699 | 0,66% | Akcje |
| GOLDMAN SACHS GROUP INC | $34 153 522 | 418 702 | 0,63% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32 274 149 | 395 662 | 0,60% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $30 892 190 | 378 720 | 0,57% | Akcje |
| Qube Research & Technologies Ltd | $25 398 777 | 311 374 | 0,47% | Akcje |
| ARMISTICE CAPITAL, LLC | $24 471 000 | 300 000 | 0,45% | Opcja kupna |
| Public Sector Pension Investment Board | $23 249 326 | 285 023 | 0,43% | Akcje |
| SEGALL BRYANT & HAMILL, LLC | $22 165 424 | 271 735 | 0,41% | Akcje |
| CITADEL ADVISORS LLC | $20 338 011 | 249 332 | 0,38% | Akcje |
| MORGAN STANLEY | $18 990 210 | 232 808 | 0,35% | Akcje |
| Boxer Capital Management, LLC | $16 314 000 | 200 000 | 0,30% | Akcje |
| RHUMBLINE ADVISERS | $15 718 994 | 192 706 | 0,29% | Akcje |
| AMERIPRISE FINANCIAL INC | $13 904 178 | 170 457 | 0,26% | Akcje |
| PRUDENTIAL FINANCIAL INC | $13 746 176 | 168 520 | 0,25% | Akcje |
| BlackRock, Inc. | $13 589 562 | 166 600 | 0,25% | Akcje |
| Rock Springs Capital Management LP | $13 238 648 | 162 298 | 0,25% | Akcje |
| Hudson Bay Capital Management LP | $13 033 091 | 159 778 | 0,24% | Akcje |
| Russell Investments Group, Ltd. | $12 687 724 | 155 544 | 0,23% | Akcje |
| Schonfeld Strategic Advisors LLC | $12 025 457 | 147 425 | 0,22% | Akcje |
| MARSHALL WACE, LLP | $11 724 301 | 143 733 | 0,22% | Akcje |
| Swiss National Bank | $11 539 300 | 141 465 | 0,21% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $11 063 583 | 135 633 | 0,20% | Akcje |
| Legal & General Group Plc | $10 362 979 | 127 044 | 0,19% | Akcje |
| CITIGROUP INC | $9 272 143 | 113 671 | 0,17% | Akcje |
| FIRST TRUST ADVISORS LP | $9 246 285 | 113 354 | 0,17% | Akcje |
| Longaeva Partners L.P. | $9 119 771 | 111 803 | 0,17% | Akcje |
| JUPITER ASSET MANAGEMENT LTD | $8 927 184 | 109 442 | 0,17% | Akcje |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $8 215 404 | 100 716 | 0,15% | Akcje |
| SECTOR GAMMA AS | $8 157 000 | 100 000 | 0,15% | Akcje |
| WCM INVESTMENT MANAGEMENT, LLC | $7 651 184 | 93 799 | 0,14% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $7 256 141 | 88 956 | 0,13% | Akcje |
| VOYA INVESTMENT MANAGEMENT LLC | $7 239 501 | 88 752 | 0,13% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $7 217 488 | 105 937 | 0,13% | Akcje |
| Aquatic Capital Management LLC | $6 808 648 | 83 470 | 0,13% | Akcje |
| XTX Topco Ltd | $6 682 459 | 81 923 | 0,12% | Akcje |
| MOORE CAPITAL MANAGEMENT, LP | $6 165 713 | 75 588 | 0,11% | Akcje |
| PINNACLE ASSOCIATES LTD | $5 745 383 | 70 435 | 0,11% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $5 744 722 | 84 320 | 0,11% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $5 614 300 | 68 828 | 0,10% | Akcje |
| Capricorn Fund Managers Ltd | $5 212 323 | 63 900 | 0,10% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5 000 241 | 61 300 | 0,09% | Opcja kupna |
| INTECH INVESTMENT MANAGEMENT LLC | $4 696 882 | 57 581 | 0,09% | Akcje |
| ExodusPoint Capital Management, LP | $4 672 166 | 57 278 | 0,09% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $4 561 884 | 55 926 | 0,08% | Akcje |
| BARCLAYS PLC | $4 169 858 | 51 120 | 0,08% | Akcje |
| ORBIMED ADVISORS LLC | $4 005 087 | 49 100 | 0,07% | Akcje |
| MetLife Investment Management, LLC | $3 932 653 | 48 212 | 0,07% | Akcje |
| Point72 Europe (London) LLP | $3 829 919 | 62 407 | 0,07% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $3 792 516 | 46 494 | 0,07% | Akcje |
| Phocas Financial Corp. | $3 766 087 | 46 170 | 0,07% | Akcje |
| MARTINGALE ASSET MANAGEMENT L P | $3 627 826 | 44 475 | 0,07% | Akcje |
| Quadrature Capital Ltd | $3 589 488 | 44 005 | 0,07% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3 531 981 | 43 300 | 0,07% | Opcja sprzedaży |
| STATE OF WISCONSIN INVESTMENT BOARD | $3 436 299 | 42 127 | 0,06% | Akcje |
| CREDIT AGRICOLE S A | $3 344 370 | 41 000 | 0,06% | Akcje |
| Fisher Asset Management, LLC | $3 322 345 | 40 730 | 0,06% | Akcje |
| HSBC HOLDINGS PLC | $3 200 425 | 38 732 | 0,06% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $3 134 490 | 38 427 | 0,06% | Akcje |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $3 114 179 | 38 178 | 0,06% | Akcje |
| CenterBook Partners LP | $3 082 938 | 37 795 | 0,06% | Akcje |
| Rafferty Asset Management, LLC | $3 069 805 | 37 634 | 0,06% | Akcje |
| FIFTH THIRD BANCORP | $3 044 843 | 37 328 | 0,06% | Akcje |
| BURNEY CO/ | $3 044 192 | 37 320 | 0,06% | Akcje |
| Vanguard Global Advisers, LLC | $3 033 180 | 37 185 | 0,06% | Akcje |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | $3 007 731 | 36 873 | 0,06% | Akcje |
| Louisiana State Employees Retirement System | $2 969 148 | 36 400 | 0,05% | Akcje |
| JANE STREET GROUP, LLC | $2 854 950 | 35 000 | 0,05% | Opcja sprzedaży |
| CASTLEARK MANAGEMENT LLC | $2 765 223 | 33 900 | 0,05% | Akcje |
Insiderzy spółki 33 insiderów · 13 dyrektorzy generalni · 14 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Stuart Walter Peltz | Chief Executive Officer | 1 lutego 2022 S | 38 728 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 lipca 2026 S | 83 986 | 0 | 1 | $-280 743 |
| Emily Luisa Hill | Chief Financial Officer | 1 lutego 2022 S | 37 169 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 maja 2017 M | 37 850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 stycznia 2015 M | 39 247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 lutego 2020 M | 6 744 | 0 | 0 | $0 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 lipca 2026 M | 60 299 | 0 | 20 | $-9 184 852 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 6 lipca 2026 M | 105 272 | 0 | 12 | $-1 254 986 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 czerwca 2026 M | 70 199 | 0 | 1 | $-1 487 474 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 czerwca 2026 S | 73 411 | 0 | 28 | $-7 477 160 |
| Mark Rothera | Chief Commercial Officer | 24 maja 2017 M | 33 739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 stycznia 2017 A | 6 000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 stycznia 2016 A | 3 239 | 0 | 0 | $0 |
| Hege Elisabeth Sollie-Zetlmayer | Dyrektor | 28 lipca 2026 A | 52 526 | 0 | 0 | $0 |
| Mary L. Smith | Dyrektor | 9 lipca 2026 M | 21 813 | 0 | 2 | $-1 425 060 |
| Stephanie Okey | Dyrektor | 7 stycznia 2022 A | 4 163 | 0 | 0 | $0 |
| Emma Reeve | Dyrektor | 7 stycznia 2022 A | 7 528 | 0 | 0 | $0 |
| Allan Steven Jacobson | Dyrektor | 7 stycznia 2022 A | 8 348 | 0 | 0 | $0 |
| Dawn Svoronos | Dyrektor | 7 stycznia 2022 A | 29 755 | 0 | 0 | $0 |
| Jerome B Zeldis | Dyrektor | 7 stycznia 2022 A | 6 500 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Dyrektor | 3 stycznia 2017 A | — | 0 | 0 | $0 |
| Adam Koppel | Dyrektor | 3 stycznia 2017 A | 2 333 333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Dyrektor | 3 stycznia 2017 A | — | 0 | 0 | $0 |
| Richard Aldrich | Dyrektor | 8 czerwca 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Dyrektor | 16 marca 2015 S | 2 242 | 0 | 0 | $0 |
| Axel Bolte | Dyrektor | 25 czerwca 2013 P | 20 000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Posiadacz 10% | 17 grudnia 2013 S | 2 441 504 | 0 | 0 | $0 |
| Matthew B. Klein | — | 4 sierpnia 2026 S | 383 868 | 0 | 1 | $-705 722 |
| Michael Schmertzler | — | 2 stycznia 2026 A | 163 266 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | — | 2 stycznia 2026 A | 22 500 | 0 | 1 | $-916 200 |
| David P Southwell | — | 2 stycznia 2026 A | 20 850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | — | 28 kwietnia 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | — | 25 czerwca 2013 C | 2 256 882 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 3 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 zgłoszenia | 30 stycznia 2015 | — | Pierwotne zgłoszenie | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 zgłoszenia | 12 listopada 2014 | — | Pierwotne zgłoszenie | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 lipca 2013 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 87 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,81% | 4 145 SH | 8 sierpnia 2026 | Dziennie |
| PSCH · Invesco Exchange-Traded Fund Trust … | 3,08% | 71 992 SH | 8 sierpnia 2026 | Dziennie |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 128 216 SH | 8 sierpnia 2026 | Dziennie |
| XSMO · Invesco Exchange-Traded Fund Trust | 1,52% | 642 023 SH | 8 sierpnia 2026 | Dziennie |
| BBP · ETFis Series Trust I | 1,37% | 12 510 NS | 30 kwietnia 2026 | N-PORT |
| SIXS · EXCHANGE TRADED CONCEPTS TRUST | 1,30% | 22 380 NS | 31 maja 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,25% | 23 662 SH | 8 sierpnia 2026 | Dziennie |
| GURU · Global X Funds | 1,03% | 9 268 NS | 30 kwietnia 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 73 928 NS | 30 kwietnia 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,83% | 10 625 NS | 30 kwietnia 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98 733 SH | 8 sierpnia 2026 | Dziennie |
| VMAX · Lattice Strategies Trust | 0,72% | 5 120 NS | 30 kwietnia 2026 | N-PORT |
| IJT · iShares Trust | 0,66% | 770 376 SH | 8 sierpnia 2026 | Dziennie |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 40 257 NS | 30 kwietnia 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,49% | 3 490 NS | 31 maja 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,49% | 40 488 NS | 31 maja 2026 | N-PORT |
| IBB · iShares Trust | 0,44% | 588 017 SH | 8 sierpnia 2026 | Dziennie |
| HQGO · Lattice Strategies Trust | 0,43% | 3 203 NS | 30 kwietnia 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,41% | 4 514 SH | 8 sierpnia 2026 | Dziennie |
| OASC · Unified Series Trust | 0,40% | 4 569 NS | 31 maja 2026 | N-PORT |
| BRNY · EA Series Trust | 0,40% | 34 057 NS | 30 kwietnia 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290 018 SH | 8 sierpnia 2026 | Dziennie |
| XJR · iShares Trust | 0,37% | 9 802 SH | 8 sierpnia 2026 | Dziennie |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,34% | 35 034 NS | 31 maja 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75 795 SH | 8 sierpnia 2026 | Dziennie |
| ESSC · Strategy Shares | 0,34% | 1 335 NS | 30 kwietnia 2026 | N-PORT |
| IJR · iShares Trust | 0,32% | 5 058 562 SH | 8 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,31% | 641 280 SH | 8 sierpnia 2026 | Dziennie |
| BIB · ProShares Trust | 0,31% | 3 062 NS | 31 maja 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,31% | 11 451 NS | 31 maja 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,30% | 39 411 NS | 31 maja 2026 | N-PORT |
| SAA · ProShares Trust | 0,26% | 961 NS | 31 maja 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 22 443 NS | 30 kwietnia 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 27 276 NS | 30 kwietnia 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,23% | 2 877 NS | 30 kwietnia 2026 | N-PORT |
| AFSM · First Trust Exchange-Traded Fund VI… | 0,23% | 3 003 NS | 31 maja 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477 030 SH | 8 sierpnia 2026 | Dziennie |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,20% | 39 967 NS | 30 kwietnia 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1 099 640 SH | 8 sierpnia 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,18% | 72 691 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,18% | 2 102 256 SH | 8 sierpnia 2026 | Dziennie |
| LRGF · iShares Trust | 0,16% | 84 151 SH | 8 sierpnia 2026 | Dziennie |
| ISCG · iShares Trust | 0,16% | 22 792 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,16% | 34 125 NS | 30 kwietnia 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11 071 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,15% | 3 710 NS | 31 maja 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35 428 SH | 8 sierpnia 2026 | Dziennie |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 49 932 NS | 30 kwietnia 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,14% | 5 350 SH | 8 sierpnia 2026 | Dziennie |
| SMDX · Tidal Trust III | 0,13% | 2 579 NS | 30 kwietnia 2026 | N-PORT |